In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Growth

Set Alert for Growth

Europe’s Big Pharma Players Begin Tricky 2022 In Style

Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.

Europe Growth

Providing A Better Last Mile Experience For Medtech And Patients

Every part of health care today needs connectivity, says Cisco’s Troy Yoder. He explaines the unique role the company’s technology plays in ensuring patients get the best care the medtech industry can offer.

Digital Health Medical Device

2021 Global Biopharma R&D Productivity And Growth Ranking

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

Growth Research & Development

A Guiding Hand For Biotech Start-Ups In Turbulent Times

Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.

Rising Leaders Financing

A Tricky Outlook, But Medtech Has Opportunities To Grow

In Vivo editorial advisory board member and ZS principal Brian Chapman identifies the agenda-topping themes for medtech bosses.

Medical Device Strategy

5 Dealmaking Trends To Watch In 2022

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Deals Companies

2021 Deal-Making Snapshot

M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.

Deals M & A

2021 Venture Investment Was Bullish – Will 2022 Be The Same?

The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?

Growth Commercial

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Growth Business Strategies

Turning The Dial Up On Digital

The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.

BioPharmaceutical Digital Health

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Outlook 2022 Growth

Infographic: Top 100 Pharma Companies

The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales. 

Outlook 2022 Commercial
See All
UsernamePublicRestriction

Register